- Cord Blood Registry (CBR) by Generate Life Sciences and NantKwest (NK +6.7%) announces collaboration for development of COVID-19 treatment leveraging newborn stem cells.
- CBR will provide research-donated umbilical cord tissue-derived mesenchymal stem cells
- Patient trials expected to begin in the fall, and both companies anticipate an FDA-approved treatment to be in the market for use in Covid-19 patients by early 2021.
NantKwest in Pact with Generate Life’s CBR on potential COVID-19 treatment
Recommended For You
About IBRX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
IBRX | - | - |
ImmunityBio, Inc. |